Small Molecule Drug Substance Outsourcing Drivers

In Q2 of 2022, ISR asked 57 respondents who outsourcer small molecule API which reason fits best with their company’s capacity for and experience with manufacturing small molecule drug substance—Adequate capacity and adequate experience, Lack capacity but adequate experience, Adequate capacity but lack experience and Lack capacity and lack experience. The data shows the most common reason for outsourcing API manufacturing is a lack of capacity despite possessing in-house experience (42%). To learn more about outsourcing behaviors, follow the link to ISR’s CDMO Outsourcing Models (4^th Edition) report preview.